372 related articles for article (PubMed ID: 28790817)
21. Systems pharmacology-based approach for dissecting the active ingredients and potential targets of the Chinese herbal Bufei Jianpi formula for the treatment of COPD.
Zhao P; Li J; Li Y; Tian Y; Wang Y; Zheng C
Int J Chron Obstruct Pulmon Dis; 2015; 10():2633-56. PubMed ID: 26674991
[TBL] [Abstract][Full Text] [Related]
22. Peroxisome proliferator-activated receptor-gamma agonists as potential anti-inflammatory agents in asthma and chronic obstructive pulmonary disease.
Spears M; McSharry C; Thomson NC
Clin Exp Allergy; 2006 Dec; 36(12):1494-504. PubMed ID: 17177672
[TBL] [Abstract][Full Text] [Related]
23. The preclinical pharmacology of roflumilast--a selective, oral phosphodiesterase 4 inhibitor in development for chronic obstructive pulmonary disease.
Hatzelmann A; Morcillo EJ; Lungarella G; Adnot S; Sanjar S; Beume R; Schudt C; Tenor H
Pulm Pharmacol Ther; 2010 Aug; 23(4):235-56. PubMed ID: 20381629
[TBL] [Abstract][Full Text] [Related]
24. What is in the guidelines about the pharmacological treatment of chronic obstructive pulmonary disease?
López-Campos JL; Calero Acuña C
Expert Rev Respir Med; 2013 Apr; 7(2 Suppl):43-51. PubMed ID: 23551023
[TBL] [Abstract][Full Text] [Related]
25. Positioning new pharmacotherapies for COPD.
Barjaktarevic IZ; Arredondo AF; Cooper CB
Int J Chron Obstruct Pulmon Dis; 2015; 10():1427-42. PubMed ID: 26244017
[TBL] [Abstract][Full Text] [Related]
26. Kinases as Novel Therapeutic Targets in Asthma and Chronic Obstructive Pulmonary Disease.
Barnes PJ
Pharmacol Rev; 2016 Jul; 68(3):788-815. PubMed ID: 27363440
[TBL] [Abstract][Full Text] [Related]
27. Impacts of peroxisome proliferator-activated receptor-γ activation on cigarette smoke-induced exacerbated response to bacteria.
Morissette MC; Shen P; Thayaparan D; Stämpfli MR
Eur Respir J; 2015 Jan; 45(1):191-200. PubMed ID: 25034559
[TBL] [Abstract][Full Text] [Related]
28. Emerging pharmacotherapies for COPD.
Barnes PJ
Chest; 2008 Dec; 134(6):1278-1286. PubMed ID: 19059958
[TBL] [Abstract][Full Text] [Related]
29. The role of airway secretions in COPD: pathophysiology, epidemiology and pharmacotherapeutic options.
Rogers DF
COPD; 2005 Sep; 2(3):341-53. PubMed ID: 17146999
[TBL] [Abstract][Full Text] [Related]
30. Evaluation of Naringenin as a Promising Treatment Option for COPD Based on Literature Review and Network Pharmacology.
Chen Z; Chen P; Wu H; Shi R; Su W; Wang Y; Li P
Biomolecules; 2020 Dec; 10(12):. PubMed ID: 33302350
[TBL] [Abstract][Full Text] [Related]
31. A score to predict short-term risk of COPD exacerbations (SCOPEX).
Make BJ; Eriksson G; Calverley PM; Jenkins CR; Postma DS; Peterson S; Östlund O; Anzueto A
Int J Chron Obstruct Pulmon Dis; 2015; 10():201-9. PubMed ID: 25670896
[TBL] [Abstract][Full Text] [Related]
32. New treatments for chronic obstructive pulmonary disease.
Barnes PJ
Ann Ist Super Sanita; 2003; 39(4):573-82. PubMed ID: 15098577
[TBL] [Abstract][Full Text] [Related]
33. Identifying Molecular Targets for New Drug Development for Chronic Obstructive Pulmonary Disease: What Does the Future Hold?
Barnes PJ
Semin Respir Crit Care Med; 2015 Aug; 36(4):508-22. PubMed ID: 26238638
[TBL] [Abstract][Full Text] [Related]
34. Update on molecular mechanisms of corticosteroid resistance in chronic obstructive pulmonary disease.
Jiang Z; Zhu L
Pulm Pharmacol Ther; 2016 Apr; 37():1-8. PubMed ID: 26805715
[TBL] [Abstract][Full Text] [Related]
35. The Novartis view on emerging drugs and novel targets for the treatment of chronic obstructive pulmonary disease.
Compton C; McBryan D; Bucchioni E; Patalano F
Pulm Pharmacol Ther; 2013 Oct; 26(5):562-73. PubMed ID: 23748050
[TBL] [Abstract][Full Text] [Related]
36. [Novel therapeutics for COPD].
Hoshino Y; Muro S; Mishima M
Nihon Rinsho; 2011 Oct; 69(10):1826-30. PubMed ID: 22073581
[TBL] [Abstract][Full Text] [Related]
37. New bronchodilators.
Mak G; Hanania NA
Curr Opin Pharmacol; 2012 Jun; 12(3):238-45. PubMed ID: 22445544
[TBL] [Abstract][Full Text] [Related]
38. New frontiers in the treatment of comorbid cardiovascular disease in chronic obstructive pulmonary disease.
Brassington K; Selemidis S; Bozinovski S; Vlahos R
Clin Sci (Lond); 2019 Apr; 133(7):885-904. PubMed ID: 30979844
[TBL] [Abstract][Full Text] [Related]
39. Emerging targets for COPD therapy.
Barnes PJ
Curr Drug Targets Inflamm Allergy; 2005 Dec; 4(6):675-83. PubMed ID: 17305523
[TBL] [Abstract][Full Text] [Related]
40. Roflumilast for the treatment of chronic obstructive pulmonary disease.
Antoniu SA
Curr Opin Investig Drugs; 2006 May; 7(5):412-7. PubMed ID: 16729716
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
